PL2931748T3 - Przeciwciała BMP-6 - Google Patents

Przeciwciała BMP-6

Info

Publication number
PL2931748T3
PL2931748T3 PL13818045T PL13818045T PL2931748T3 PL 2931748 T3 PL2931748 T3 PL 2931748T3 PL 13818045 T PL13818045 T PL 13818045T PL 13818045 T PL13818045 T PL 13818045T PL 2931748 T3 PL2931748 T3 PL 2931748T3
Authority
PL
Poland
Prior art keywords
bmp
antibodies
Prior art date
Application number
PL13818045T
Other languages
English (en)
Inventor
Stephanie Marie Eaton Truhlar
Neungseon Seo
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49918813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2931748(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL2931748T3 publication Critical patent/PL2931748T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
PL13818045T 2012-12-17 2013-12-05 Przeciwciała BMP-6 PL2931748T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737859P 2012-12-17 2012-12-17
EP13818045.0A EP2931748B1 (en) 2012-12-17 2013-12-05 Bmp-6 antibodies

Publications (1)

Publication Number Publication Date
PL2931748T3 true PL2931748T3 (pl) 2017-05-31

Family

ID=49918813

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13818045T PL2931748T3 (pl) 2012-12-17 2013-12-05 Przeciwciała BMP-6

Country Status (34)

Country Link
US (2) US8795665B2 (pl)
EP (1) EP2931748B1 (pl)
JP (1) JP6033459B2 (pl)
KR (1) KR20150083918A (pl)
CN (1) CN104870473B (pl)
AP (1) AP2015008600A0 (pl)
AR (1) AR093620A1 (pl)
AU (1) AU2013363548A1 (pl)
BR (1) BR112015012708A2 (pl)
CA (1) CA2892911C (pl)
CL (1) CL2015001639A1 (pl)
CY (1) CY1118254T1 (pl)
DK (1) DK2931748T3 (pl)
EA (1) EA201590918A1 (pl)
ES (1) ES2608381T3 (pl)
HK (1) HK1209763A1 (pl)
HR (1) HRP20161587T1 (pl)
HU (1) HUE032431T2 (pl)
IL (1) IL239242A0 (pl)
LT (1) LT2931748T (pl)
MA (1) MA38161A1 (pl)
ME (1) ME02515B (pl)
MX (1) MX2015007831A (pl)
PE (1) PE20151164A1 (pl)
PH (1) PH12015501360A1 (pl)
PL (1) PL2931748T3 (pl)
PT (1) PT2931748T (pl)
RS (1) RS55413B1 (pl)
SG (1) SG11201504695QA (pl)
SI (1) SI2931748T1 (pl)
TN (1) TN2015000277A1 (pl)
TW (1) TW201439118A (pl)
WO (1) WO2014099391A1 (pl)
ZA (1) ZA201504282B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
EP3471759A1 (en) * 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
EP3983436A1 (en) * 2019-06-12 2022-04-20 Regeneron Pharmaceuticals, Inc. Human antibodies to bone morphogenetic protein 6
US20230203196A1 (en) * 2020-04-07 2023-06-29 Mabwell Therapeutics Inc. Anti-tmprss6 antibodies and uses thereof
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077006A1 (en) 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
ES2766257T3 (es) * 2008-11-13 2020-06-12 Massachusetts Gen Hospital Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
US20110070242A1 (en) 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6

Also Published As

Publication number Publication date
KR20150083918A (ko) 2015-07-20
AP2015008600A0 (en) 2015-07-31
US20140170161A1 (en) 2014-06-19
PT2931748T (pt) 2016-11-02
CN104870473B (zh) 2018-05-29
WO2014099391A1 (en) 2014-06-26
US8795665B2 (en) 2014-08-05
PE20151164A1 (es) 2015-08-19
CL2015001639A1 (es) 2015-10-02
EP2931748A1 (en) 2015-10-21
HK1209763A1 (zh) 2016-04-08
AU2013363548A1 (en) 2015-05-28
ME02515B (me) 2017-02-20
CA2892911A1 (en) 2014-06-26
ZA201504282B (en) 2017-11-29
CY1118254T1 (el) 2017-06-28
JP6033459B2 (ja) 2016-11-30
TN2015000277A1 (en) 2016-10-03
MX2015007831A (es) 2015-08-20
LT2931748T (lt) 2017-01-10
EA201590918A1 (ru) 2015-10-30
CA2892911C (en) 2017-02-28
SG11201504695QA (en) 2015-07-30
US20140309404A1 (en) 2014-10-16
CN104870473A (zh) 2015-08-26
PH12015501360A1 (en) 2015-09-02
TW201439118A (zh) 2014-10-16
SI2931748T1 (sl) 2017-01-31
EP2931748B1 (en) 2016-10-05
JP2016501273A (ja) 2016-01-18
HUE032431T2 (en) 2017-09-28
US8980582B2 (en) 2015-03-17
BR112015012708A2 (pt) 2017-09-12
AR093620A1 (es) 2015-06-10
ES2608381T3 (es) 2017-04-10
HRP20161587T1 (hr) 2017-01-13
IL239242A0 (en) 2015-07-30
RS55413B1 (sr) 2017-04-28
DK2931748T3 (da) 2017-01-02
MA38161A1 (fr) 2017-12-29

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2844290A4 (en) NOVEL ANTIBODIES
EP2837685A4 (en) ANTI-FGFR2 ANTIBODIES
EP2826790A4 (en) GREMLIN-1 ANTIBODY
HK1209763A1 (zh) 抗體
HK1210186A1 (en) Anti-h7cr antibodies h7cr
PL2935330T3 (pl) Przeciwciała przeciw notch3
EP2804876A4 (en) NEW ANTIBODIES
GB201220242D0 (en) Antibody
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies